BUSINESS

Olema insiders sell millions amid analyst upgrades now

PUBLISHED Dec 23, 2025, 10:37 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 6

Center 100%

Sources: 6

United States — Olema Pharmaceuticals executives sold shares between December 19 and December 23, 2025, according to Securities and Exchange Commission filings. Chief Medical Officer Naseem Zojwalla sold $7.5 million of common stock and exercised options; Director Ian T. Clark sold $7.87 million and exercised options; David Myles sold about $1.55 million and reported ownership changes. The moves coincided with analyst price‑target increases following interim results from Roche’s Phase 3 lidERA trial and with market volatility in OLMA shares. All transactions were disclosed via SEC filings and reported by financial news services. Based on 6 articles reviewed and supporting research.

By Lauren Mitchell | JQJO News

Timeline of Events

Prior to December 2025: Olema develops OP-1250 (SERD/CERAN) as lead candidate in women's cancers.
Mid-December 2025: Roche presents interim data from its Phase 3 lidERA trial, increasing industry focus on SERD class.
Following the presentation: Analysts (H.C. Wainwright, Goldman Sachs, Jefferies) raise price targets for Olema and peers.
December 19, 2025: SEC filings show David Myles and Ian T. Clark sold shares and exercised options.
December 19–23, 2025: CMO Naseem Zojwalla sold shares and exercised options; financial outlets report market reactions.

Media Bias

Articles Published:: 6
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 6

Who Benefited

Company insiders realized personal liquidity through disclosed sales while analysts and some investors benefited from clearer price targets and updated valuations following Roche lidERA interim data.

Who Impacted

Short-term shareholders and traders exposed to OLMA volatility experienced increased uncertainty and potential unrealized losses amid price swings after the disclosures.

Media Bias

Articles Published:: 6
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 6
Distribution:: Left 0%, Center 100%, Right 0%

Who Benefited

Company insiders realized personal liquidity through disclosed sales while analysts and some investors benefited from clearer price targets and updated valuations following Roche lidERA interim data.

Who Impacted

Short-term shareholders and traders exposed to OLMA volatility experienced increased uncertainty and potential unrealized losses amid price swings after the disclosures.